ALTG 10/001 TROG 11.03 PLUNG-GP: Randomised phase III trial of high dose palliative radiotherapy (HDPRT) vs concurrent chemotherapy and HDPRT (C-HDPRT) in patients with good performance status, locally advanced/small volume metastatic NSCLC not suitable for radical chemo-radiotherapy – M Lehman

The TROG 11.03 PLUNG-GP trial is a randomised Phase III trial comparing high dose palliative radiotherapy (HDPRT) with concurrent chemotherapy + HDPRT (C-HDPRT) in patients with good performance status, locally advanced or small volume metastatic NSCLC who are not suitable for radical chemo-radiotherapy, either due to tumour extent or patient factors. The optimal treatment approach for this group of patients is unknown and clinical practice varies throughout Australia. The PLUNG trial compares a widely employed high dose palliative radiotherapy regime (36Gy/12F) with a concurrent chemotherapy and high dose palliative radiotherapy regime (40Gy/20F + Vinorelbine + Cisplatin) which has been investigated in preceding Phase I and II trials conducted under the auspices of the Trans Tasman Radiation Oncology Group (TROG).

The objectives of the trial are to determine which regime is superior in terms of symptom relief and improvement in quality of life. The study recruited 76 patients and closed to follow-up on 31 July 2018.

For anyone who is interested in this study please contact either A/Prof Margot Lehman margot.lehman@health.qld.gov.au or A/Prof Michael Michael michael.michael@petermac.org

Study Contacts
Trial Chair: A/Prof Margot Lehman     margot.lehman@health.qld.gov.au

Trial Co-ordinator: Adrienne See, Princess Alexandra Hospital     adrienne.see@health.qld.gov.au

Upcoming Events
  1. ALTG open MAC and SAC meetings

    November 20
  2. Virtual 2020 World Conference on Lung Cancer Singapore

    January 28, 2021 @ 8:00 am - January 31, 2021 @ 5:00 pm